Just 6 months into the job, GSK’s CEO is spearheading some big moves. The London-based pharma giant announced Tuesday that it ...

GSK plc on Tuesday agreed to acquire Boston-based biotech firm Nuvalent, Inc. for $10.6 billion in cash as the British ...

Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s ...

By Bhanvi Satija and Yadarisa Shabong LONDON, June 9 (Reuters) - GSK has agreed to buy U.S.-listed cancer drug developer ...

GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where the stock traded as of Monday’s ...

The FTSE 100 index dropped by 0.3% on Tuesday, primarily influenced by GSK's decision to acquire U.S.-based drug developer ...

British pharmaceutical giant GSK plc (LON:GSK) is reportedly in advanced negotiations to acquire U.S.-based cancer drug ...

GSK PLC on Tuesday said it has agreed to US-based cancer drug developer Nuvalent Inc for USD10.6 billion. The announcement confirmed a Financial Times report published early Tuesday. The final USD10.6 ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion. By Rebecca Robbins The British drug maker GSK said on Wednesday that it ...

May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug, ...

GSK's largest acquisition in recent years, a $10.6 billion purchase of cancer drug developer Nuvalent, signifies a new ...